T9052 |
XL092
|
2367004-54-2
|
99.51%
|
|
XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
|
T5S1331 |
Herbacetin
|
527-95-7
|
99.51%
|
|
1. Herbacetin induces apoptosis in HepG2 cells, by ROS and PI3K/Akt pathway. 2. Herbacetin suppresses the HGF-induced motility of human breast cancer MDA-MB-231 ...
|
T2185 |
L-Ascorbic acid 2-phosphate trisodium
|
66170-10-3
|
99.5%
|
|
L-Ascorbic acid 2-phosphate trisodium (Sodium ascorbyl phosphate) is used in biocatalytic dephosphorylation for electric power generation and electrochemical det...
|
T10585 |
Bozitinib
|
1440964-89-5
|
99.48%
|
|
Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability. Bozitinib binds to the conventional AT...
|
T4426 |
CEP-40783
|
1437321-24-8
|
99.45%
|
|
CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).
|
T5478 |
SRI 31215 TFA
|
1832686-44-8
|
99.36%
|
|
SRI 31215 TFA, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF ...
|
T6128 |
PHA-665752
|
477575-56-7
|
99.35%
|
|
PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
|
T1661 |
Crizotinib
|
877399-52-5
|
99.35%
|
|
Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.
|
T22324 |
Ensartinib hydrochloride
|
2137030-98-7
|
99.29%
|
|
Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known cr...
|
T6260 |
AMG-208
|
1002304-34-8
|
99.27%
|
|
AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.
|
T8416 |
Capmatinib xHCl
|
1029714-89-3
|
99.24%
|
|
Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50 =...
|
T2699 |
BMS 777607
|
1025720-94-8
|
99.22%
|
|
BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3 (IC50: 3.9/1.1/1.8/4.3 nM). BMS-777607 has been investigated for the basic science of ...
|
T6351 |
MGCD-265 analog
|
875337-44-3
|
99.21%
|
|
MGCD-265 analog (Glesatinib) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 10 n...
|
T13108 |
Pamufetinib
|
1190836-34-0
|
99.15%
|
|
Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rME...
|
T1797 |
Cabozantinib S-malate
|
1140909-48-3
|
98.87%
|
|
Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with pot...
|
T2349 |
BMS-754807
|
1001350-96-4
|
98.86%
|
|
Dual IGF-1R/InsR Inhibitor BMS-754807 is an oral small molecule inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine ...
|
T8409 |
SYN1143
|
913376-84-8
|
98.86%
|
|
SYN1143 (AMG-1) is a potent inhibitor of human RON and c-Met.In vitro kinase assays showed that compound I is a potent inhibitor of human RON and c-Met with IC50...
|
T15617 |
JNJ-38877618
|
943540-74-7
|
98.84%
|
|
JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).
|
T3550 |
X-376
|
1365267-27-1
|
98.72%
|
|
X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic...
|
T2680 |
NVP-BVU972
|
1185763-69-2
|
98.61%
|
|
NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.
|